Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

NCT02253927 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BILR 355 - D1
DRUG: BILR 355 - D2
DRUG: BILR 355 - D3
DRUG: BILR 355 - D4
DRUG: Ritonavir
OTHER: high fat breakfast

Sponsor

Boehringer Ingelheim